Next Article in Journal
Isolation and Identification of Culturable Bacteria from South China Seawater and Preliminary Screening of Marine Biocontrol Bacteria
Previous Article in Journal
Multi-Generation Ecosystem Selection of Rhizosphere Microbial Communities Associated with Plant Genotype and Biomass in Arabidopsis thaliana
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Actinomyces spp. Prosthetic Vascular Graft Infection (PVGI): A Multicenter Case-Series and Narrative Review of the Literature

by
Giovanni Del Fabro
1,*,
Sara Volpi
2,
Benedetta Fumarola
1,
Manuela Migliorati
1,
Davide Bertelli
1,
Liana Signorini
1,
Alberto Matteelli
1 and
Marianna Meschiari
2
1
Department of Infectious Diseases, Spedali Civili di Brescia, University of Brescia, 25123 Brescia, Italy
2
Clinic of Infectious Diseases, University Hospital of Modena, 41124 Modena, Italy
*
Author to whom correspondence should be addressed.
Microorganisms 2023, 11(12), 2931; https://doi.org/10.3390/microorganisms11122931
Submission received: 15 September 2023 / Revised: 26 November 2023 / Accepted: 30 November 2023 / Published: 6 December 2023
(This article belongs to the Section Medical Microbiology)

Abstract

:
Background: Actinomycosis represents a challenging and under-reported complication of vascular surgery. Optimal management of Actinomyces spp. prosthetic vascular graft infection (PVGI) is highly uncertain because of the paucity of reports on this disease. Methods: We conducted a retrospective case-series of Actinomyces-PVGI that occurred in the last five years in two major university hospitals in northern Italy. We searched for previously published cases in the scientific literature. Results: We report five original cases of Actinomyces spp. prosthetic vascular graft infection following aortic aneurysm repair. Our literature review retrieved eight similar cases. Most patients were immunocompetent males. Most infections were polymicrobial (11/13 cases), with a prevalence of A. odontolyticus involvement (3/13 cases were associated with. Salmonella spp. infection). All cases had a late presentation (≥4 months from graft placement), with 61% associated with an aorto-enteric fistula. All patients received antibiotic therapy, but the duration was highly heterogeneous (from two weeks to life-long antibiotics). The patients without surgical revision experienced septic recurrences (2/13), permanent dysfunction (1/13), or a fatal outcome (2/13), while of the remainder who underwent vascular graft explant, six recovered completely and one developed a periprosthetic abscess. In two cases follow-up was not available. Conclusions: This case-series aims to raise the diagnostic suspicion and to describe the current management of Actinomyces-PVGIs. We highlight a high heterogeneity in antibiotic duration, choice of the antibiotic regimen, and surgical management. Higher reporting rate is advisable to produce better evidence and optimize management of this rare complication of vascular surgery.

1. Introduction

Actinomyces is an anaerobic Gram-positive rod residing on mucosal surfaces of the gastrointestinal, respiratory, and urogenital tracts. It can cause endogenous infections, of which the most common forms are orocervical, thoracic, abdominal, and pelvic actinomycosis [1,2]. However, actinomycosis can virtually affect any body site. Some examples of unusual presentations include gallbladder infection, pericarditis, infection of the penile shaft, infected lymphocele, and infections of prosthetic joints [3,4,5,6]. Actinomyces spp. bloodstream infections (BSI), eventually causing endocarditis, have been reported [7,8]. Actinomyces has never been well-characterized as a pathogen complicating vascular surgery procedures.
In the present study, we report five cases of prosthetic vascular graft infection (PVGI) caused by Actinomyces spp., and we provide a review of other cases in the literature. The aim of this narrative review is to describe the presentation, microbiological characteristics, treatment management, and outcomes of Actinomyces-PVGI.

2. Materials and Methods

A retrospective data collection was conducted to identify all adult patients with a diagnosis of PVGI caused by Actinomyces spp., occurring from 1 January 2018 to 1 January 2023 in two tertiary care centers in northern Italy (University Hospitals of Brescia and Modena). Inclusion criteria included age ≥18 years, a diagnosis of PVGI based on MAGIC criteria (at least one major clinical/radiological/laboratory criterion, plus any other criterion from another category, see [9]) associated with the detection of Actinomyces spp. in intra-operative samples or in blood-cultures. Exclusion criteria included suspect PVGI cases that did not meet MAGIC criteria for diagnosis, lack of consent for publication, absence of microbiological diagnosis, and patients lost to follow-up at 3-months. Data relative to primary graft implant, infection signs, microorganisms involved, surgical and medical treatment, and outcomes were retrieved from electronic medical records. The study was conducted in accordance with the Declaration of Helsinki, and all subjects (or next-of-kin for dead patients) gave their informed consent for anonymous publication of data. Because of the retrospective nature of data collection, ethics approval was waived for the study. A narrative review of the English, Italian and French-language literature on Actinomyces-PVGI was conducted in PubMed/NCBI, Google Scholar and other similar databases. The primary aim of this review was to identify previous cases of PVGI by Actinomyces spp. in order to describe the number of previously published cases. Secondary objectives were to identify the patients’ characteristics and their clinical management. Key search terms were “actinomyces” OR “actinomycosis” cross-referenced with “vascular infection” OR “vascular graft” OR “vascular prosthesis” OR “vascular surgery”. Inclusion criteria included adult patients with aortic graft infection, the presence of detailed description of microbiological results in the report, and a definite microbiological diagnosis (Actinomyces spp. identification in the intraoperative samples or in blood cultures). Reports not providing details on patient characteristics, clinical management, and outcome were included only if they provided sufficient details on diagnostic definition of Actinomyces-PVGI. Studies regarding animals or experimental models, duplicate papers and cases without a definite microbiological diagnosis were excluded. The remaining papers were reviewed, and all papers that did not specifically comprise cases of PVGI (as indicated in the title or abstract) were excluded. After applying these criteria, 14 papers were included in the literature review. The results of this search are listed in the Results Section 3.2 and commented on in Section 4.

3. Results

3.1. Case Series

Case 1: A 73-year-old male patient underwent endovascular repair (EVAR) and sigmoidectomy for abdominal aortic aneurysm (AAA) rupture with intestinal ischemia in August 2021. Seven months later, he was admitted for abdominal pain and hemoptysis. A CT-scan revealed a periprosthetic fluid collection with air bubbles and an aorto-enteric fistula (AEF). Graft replacement and partial ileal resection were performed. The intraoperative samples isolated Actinomyces odontolyticus and Candida albicans. Two weeks of meropenem plus micafungin were followed by eleven months of fluconazole and long-term amoxicillin. After seven months, a CT-scan showed a new appearance of periprosthetic left psoas abscess. The patient refused any new intervention, therefore suppressive antibiotic therapy was established. At the two-year follow-up, the patient was clinically and radiologically stable, with no signs of systemic infection.
Case 2: A 81-year-old male patient underwent an EVAR procedure for AAA by Salmonella spp. in January 2021. Six months later, he was readmitted for fever and lumbar pain. A PET/CT-scan revealed a periprosthetic collection with increased glucidic uptake. Debridement and graft replacement were performed. The intraoperative cultures identified Salmonella spp. and A. odontolyticus. Twelve weeks of intravenous β-lactams were followed by 12 months of oral amoxicillin. At the two-year follow-up, the patient had no relapse.
Case 3: A 77-year-old male patient underwent aorto-bisiliac prosthesis placement for AAA in 2014. Three years later, it was complicated by endoleak and AEF, requiring aneurysmatic-sac embolization and surgical repair. In May 2018, he presented with fever, lumbar pain and anemia. CT-angiography showed PVGI and a new AEF. Blood cultures isolated A. odontolyticus. Due to his poor health status, a conservative management with oral amoxicillin was attempted. The patient died from an aneurysmatic rupture 37 days after the onset of the infection.
Case 4: In May 2018, a 69-year-old man underwent an emergency EVAR because of a AAA rupture. The rupture was suspected to be infectious based on its uptake at CT-scan, although without any microbiological isolate. Three months later, he was readmitted for sepsis due to A. odontolyticus and S. anginosus bloodstream infection (BSI). Salmonella spp. grew from stool cultures. A PET/CT-scan showed increased uptake of the endovascular prosthesis. PVGI was confirmed at open surgery and prosthesis explant was performed. Given the negativity of all the intraoperative samples, antibiotic therapy was stopped two weeks after surgery. At the three-year follow-up, the patient had no relapse, with significant reduction of the uptake at the PET/CT-scan.
Case 5: A 76-year-old woman underwent an EVAR procedure for AAA by Salmonella spp. in December 2020. The course was complicated by abscessualization of the aneurysmatic-sac and vertebral osteomyelitis, requiring surgical drainage, vertebral stabilization, and twelve weeks of antibiotic therapy. Four months later, she was readmitted for spinal implant infection (requiring implant removal) and polymicrobial BSIs by S. aureus, E. coli, and Actinomyces spp. A PET/CT-scan showed an increased uptake of the vascular prosthesis, suspicious for PVGI. Due to her poor health status, explant of the vascular graft was infeasible. Long-term antibiotic treatment was started. The patient died in an end-of-life-residency seven months later.
All cases are summarized in Table 1 and Table 2.

3.2. Literature Review

We could find only six detailed reports of PVGI by Actinomyces spp. specifically involving aortic grafts [10,11,12,13,14,15], with five in English and one in French. Two distinct cases of PVGI caused by Actinomyces odontolyticus by the same author were identified in a study focusing on performance of graft culture with and without sonication [16] and in one study focusing on vascular infection by Coxiella burnetii [17]. Even if no complete clinical details were reported, we retained the two cases as valuable. Four additional cases were found in retrospective cohort studies of patients with vascular graft complicated by an AEF [18] or infection [19,20,21], but they were not included because no specific information was provided.
Two further cases of actinomycosis (identification of Actinomyces oris and israelii) associated with percutaneous coronary intervention (performed four months before) were retrieved from the literature search [22,23]. Because of the different anatomical setting and presentation, these two reports were not included in the list of PVGI cases caused by Actinomyces spp.
The significant findings from the literature search [10,11,12,13,14,15,16,17] are summed-up in Table 3 and Table 4. All eight cases occurred in male patients with an age ranging from 54 to 79 years. Seven cases (88%) were associated with AEF (in the case of Howgego et al., the AEF was primary) [10,11,12,13,14,15,16], but in the remaining case [17] an aorto-duodenal “close contact” was reported. In all cases, the presentation was delayed (>4 months after implant), with a time from graft implant to Actinomyces spp. infection ranging from >4 months to eight years. Polymicrobial infection was the most common (7/8 cases, 88%). Only in one case a monomicrobial infection by Actinomyces spp. was described [16]. However, this episode was preceded two years before by a septic episode with microbiological identification of Streptococcus milleri, Eikenella corrodens, and Bacteroides sp.
The management was heterogeneous. In three cases, a conservative approach was attempted [10,13,15]. In the case presented by Delarbre, this approach was initially attempted, with no success. After failure, surgical debridement with complete removal of the infected graft was performed [10]. Debridement with complete vascular prosthesis removal and AEF repair were performed in four cases [10,11,12,14]. In two cases, the management is unknown [16,17]. Antibiotic duration after surgical procedure ranged from two weeks [10] to long-term therapy [12,13,15]. Patients treated with surgery [10,11,14] were reported to have a full recovery (in the case presented by Lane, there was no detailed follow-up after discharge [12]). Patients treated conservatively [13,15] suffered recurrent episodes of infection [13] or permanent dysfunction [15].

4. Discussion

The most common microorganisms involved in PVGI are S. aureus, coagulase-negative staphylococci, and Gram-negative bacilli (especially E. coli and P. aeruginosa) [24,25]. Only eight sufficiently detailed cases of Actinomyces-PVGI were previously reported in the literature [10,11,12,13,14,15,16,17]. So far, this case-series constitutes the largest case-series about Actinomyces-PVGI specifically involving aortic grafts.
Actinomyces spp. are an emerging cause of endocarditis [26], implying an endothelial adherence capacity that may also be involved in PVGI pathogenesis. The implanted prosthesis itself is a predisposing factor for actinomycosis due to its ability to form biofilm [1]. Biofilm-associated infections constitute a unique setting for infection development: even a low inoculum of a low-grade pathogen is sufficient to cause an implant-associated infection [27,28]. Our case-series shows that, together with intrauterine contraceptive devices [29], arthroplasties [6], mammary prosthesis [30], and intraocular implants [31], even vascular grafts appear to be susceptible to Actinomyces invasion.
Local tissue damage, poor dental status, trauma, or surgery serves as an entry site for Actinomyces [2]. PVGI may arise through three pathways: (1) contamination during graft implant procedure, (2) intestinal bacterial translocation, especially in the case of pre-existing AEF, and (3) BSI. The first two are likely the most common. Overall, considering our patients and the eight previously published cases, 61% (8/13) of patients had a secondary AEF [10,11,12,13,14,16]. AEF formation can alternatively be the cause and the effect of graft infection [32]. Intriguingly, Actinomyces infection is a recognized cause of primary AEF, often occurring in the duodenum [33,34]. Microbiological analysis of arterial aneurysms shows that bacteria can be detected in one quarter of the aneurysm walls, and anaerobic microorganisms (including Actinomyces spp.) are present in 71% of cases [35]. However, when PVGI is already present, it is almost impossible to understand if AEF is primary (causing the PVGI) or secondary to graft infection. In our case-series, three of five cases underwent an EVAR procedure because of AAA related to Salmonella spp. infection (case 2, 4, and 5). It is difficult to conclude if PVGI occurred as a consequence of a persistent infection of the aneurysmatic wall or as a consequence of bacterial translocation occurring after the graft implantation.
Actinomyces is usually involved in polymicrobial infections [1], as confirmed by our case-series and the literature review (11/13 cases, 85%) [10,11,12,14,15,16,17]. The only two cases of apparently monomicrobial infection (case 3 and Hansen et al. [13]) were not surgically treated: the absence of intraoperative samples may explain the missing identification of co-pathogens. The pathogenetic hypothesis of intestinal translocation appears to be even more relevant considering that more than half of the cases were caused by the species A. odontolyticus (8/13 cases, 61%). A. odontolyticus is a resident bacterium of the oral cavity (being the main responsible for tooth biofilm formation), pharynx, distal esophagus, and distal urinary tract [1,36]. This pathogen has been reported to cause orocervicofacial [37,38,39], laryngeal [40,41], thoracic [42,43], renal [44,45], and pelvic actinomycosis [46,47], infection of the penile shaft [4], peritonitis [48], cholecystitis [49], liver abscesses [50,51], chronic conjunctivitis [52], spinal and brain abscesses (including meningitis) [53,54,55], foot, finger, arm abscesses [56,57,58], and other soft tissues involvement, such as cutaneous abscesses [59,60], osteomyelitis [61,62], purulent pericarditis [63,64], endocarditis [65], and BSI [66,67,68,69]. Looking at implant-associated infections with the contribution of A. odontolyticus, besides PVGI caused by A. odontolyticus [10,14,16,17], reports exist on endocarditis related to implantable cardioverter defibrillator [70], IUCD-associated pelvic actinomycosis [71,72], and dental implant fixtures infection [73]. Dental or oral conditions [54,63,64], intravenous drug abuse [60,67], toothpick skin puncture [56], surgery of the gastrointestinal tract [62], laryngeal injections [41], and urologic procedures [4,45,74] have been implicated in A. odontolyticus infection.
Considering host predisposing factors, the male gender is known to be associated with actinomycosis [1]. That was confirmed in our case-series and review, since 80% (4/5) of our patients and 100% of the previously reported cases were males [10,11,12,13,14,15,16,17]. In our case-series the mean age was 75.2 years (range: 69–81 years), quite in line with previous cases of Actinomyces-PVGI [10,11,12,13,14,15,17]. Dental status is associated with actinomycosis and dental procedures are known to produce transient Actinomyces spp. bacteriemia [1,75]. In the case of Delarbre et al., periodontal disease was documented [10]. Detailed information on dental status is lacking in our case-series, as it is not routinely reported on clinical charts. Dampened immune status has been associated with actinomycosis [2], but in our cohort it was not possible to detect significant immunosuppressive conditions. Only case 4 had a cardias adenocarcinoma treated with surgery, chemotherapy and radiotherapy, predisposing him to mucosal damage. Also chronic kidney disease (CKD), present in case 3, has been associated with increased permeability of gastrointestinal mucosa, together with immune dysfunction [76,77]. A discrete number of single-case reports of actinomycosis in patients with CKD, including end-renal disease, have been published, suggesting a possible association between the two diseases [10,78,79].
The diagnosis of actinomycosis requires a high index of suspicion. Culture identification is not granted, as no good selective media exists, and anaerobic conditions together with long incubation are required [80,81]. Case-series on actinomycosis report that more than 40% cases are culture negative [82]. No special media is required, but it has been suggested that semi-selective media may increase isolation rates of Actinomyces when more rapidly growing organisms are also present [83]. Still, the polymicrobial nature of infection, mistakes in sample handling and transport (anaerobic conditions not respected), or too short incubation (at least 10 days is advisable) make it difficult to identify this slow-growing germ [80,81]. For this reason, historically, most cases of actinomycosis were identified via histopathological examination [80]. A typical finding is a granulomatous infection characterized by the presence of sulfur granules with Gram-positive filamentous branching bacteria at the periphery [2]. Carrara et al., showed the added value of histopathology compared to traditional cultures in the diagnosis of pelvic actinomycosis [84]. However, histology is not routinely performed during revisions of vascular surgery, likely contributing to under-diagnose Actinomyces-PVGI. Polymerase chain reaction (PCR) has been shown to be more sensitive than microbiological cultures in the setting of oral and pelvic actinomycosis [85,86]. Two recent studies about the microbiological identification in PVGI of other etiologies showed promising results of PCR techniques and sonication [16,87]. Those tools may soon become a diagnostic standard for vascular graft-associated infections, leading to increased recognition of underreported species. With the spread of molecular techniques based on PCR, such as 16s rRNA identification, and mass spectrometry techniques, including MALDI-TOF, it is expected that the diagnostic sensitivity of Actinomyces spp. implant-associated infection will improve, and so will the reporting rate [81,85,86].
In general, PVGI of any cause requires prosthesis explant, extensive debridement, and fistula repair to achieve infection eradication [88]. Antibiotics alone are at increased risk of clinical failure [24]. Indeed, when a conservative approach was attempted in Actinomyces-PVGI (case 3, case 5, the cases reported by Hansen [13] and Howgego [15], and the first approach to the case reported by Delarbre [10]), an unfavorable outcome was experienced (septic recurrences or uncontrolled infection in two cases [10,13], permanent dysfunction in one case [15], and a fatal outcome in two patients). Of the seven patients treated with graft explant, six recovered completely (case 2, case 4, the cases reported by Delarbre [10], Bush [11], Lane [12] and Blank [14]) and only one lately suffered of secondary psoas abscess (case 1). Following the surgical explant of the infected graft, vascular functionality was achieved through graft replacement (four cases; see cases 1, 2, 4, and the case by Delarbre [10]) or with a bypass (three cases, see cases [11,12,14]). Due to the small number of cases and the number of factors that influence the choice, it is not possible to assess which reconstruction type is preferable. A recent meta-analysis on PVGI of any cause aimed to assess and compare the effects of surgical and medical interventions, but it was inconclusive due to the lack of good evidences on this topic [89].
In our case-series, the length of antimicrobial therapy ranged from five weeks (case 4) to long-life suppression (case 1). The heterogeneity in treatment duration is also evident from the literature review (ranging from two weeks to life-long suppression). This variety is explainable by the lack of consensus on optimal antimicrobial treatment duration for both PVGI and Actinomyces infections [1,24]. Recommended duration of antibiotics in general PVGI is based on expert opinions, and American and European guidelines suggest a minimum of 2–4 weeks of intravenous antibiotics followed by oral therapy for a variable duration (2 weeks to life-long) [24,90]. In the case of graft replacement and adequate source control, European guidelines indicate that a total duration of 4–6 weeks of antimicrobial therapy might be sufficient [24]. Actinomyces spp. are usually susceptible to unprotected penicillins, and traditionally, they were treated with an “intensive phase” of intravenous antibiotics (2–6 weeks) followed by oral amoxicillin for at least 6 months [1]. More recent data, however, showed excellent results with shorter courses of antibiotics when associated with surgery [91,92,93]. It has been suggested that antimicrobial duration in actinomycosis infection should be tailored to the clinical and radiological response and the initial burden of disease [93], but the absence of clear guidelines makes it difficult to apply shorter antimicrobial courses in clinical routine. Looking at previously reported cases of Actinomyces-PVGI, in three cases (all associated with the surgical removal of the infected graft) postoperative antibiotics were given for less than two months, with a good final outcome [10,11,14]. Sound evidence addressing Actinomyces-PVGI is lacking, but it seems reasonable to conclude that antibiotic therapy might be safely shortened when adequate source control is achieved, in line with European guidelines for graft infections [24].
Besides duration, the choice of the antibiotic molecule deserves some consideration. Penicillins are considered the drug of choice for historical reasons, but there are no randomized control studies evaluating the efficacy of alternative regimens effective in vitro [94,95,96,97,98]. Several reports showed effective cure of actinomycosis with ceftriaxone, carbapenems, macrolides, and doxycycline [14,91,99,100,101]. Tetracyclines represent an attractive oral option in actinomycosis because of their good bioavailability and tissue penetration. They have been used with clinical success, and due to their favorable pharmacokinetic profile, they also appear to be a valuable option in Actinomyces-PVGI [14]. However, tetracyclines resistance (up to 30% of isolates) has been reported, so they should be used only with documented susceptibility [94,97,102]. A major limitation affecting the choice of therapy is that identification by culture is not easy and, even if available, susceptibility tests for anaerobes are not routinely performed in many laboratories, with interpretation being limited to CLSI breakpoints. The E-test method is not the gold standard for anaerobic bacteria, but it is more practical and cost-effective then the agar dilution method. In a recent work on oral isolates, a strain of A. odontolyticus resistant to benzylpenicillin, meropenem, moxifloxacin, and daptomycin was detected [103]. Surveillance data and clinical studies raise concerns about antimicrobial resistance trends in anaerobic infections [104]. Thus, routine susceptibility testing for anaerobes should be strongly encouraged to guide antimicrobial therapy.
Given the many points of uncertainty regarding Actinomyces-PVGI, a long-term follow-up with close surveillance is recommended, including laboratory tests and imaging. In particular, CT and PET/CT scans can support clinicians in managing these cases [24]. In case 1, the CT-scan identified an otherwise asymptomatic periprosthetic abscess of the psoas muscle, confirming the importance of appropriate radiological follow-up.
Our results may not be generalizable due to the small number of cases, the heterogeneity of management, and the retrospective nature of data collection (with possible selection bias). Nevertheless, this descriptive study represents the largest case-series published so far, and it may increase awareness of an under-reported complication of vascular surgery. Actinomyces-PVGI following vascular graft replacement must be suspected, even in immunocompetent patients. Appropriate identification methods should be implemented because a combined approach of antibiotic therapy and surgery improves the final outcome. The optimal antimicrobial duration is currently unknown. We conclude with a call for increasing Actinomyces-PVGI reports in order to produce better evidence for the appropriate management of this disease.

Author Contributions

Conceptualization, G.D.F., S.V. and M.M. (Marianna Meschiari); methodology, G.D.F. and M.M. (Marianna Meschiari); investigation, G.D.F., S.V., B.F., M.M. (Manuela Migliorati), D.B., L.S. and A.M.; data curation, G.D.F.; writing—original draft preparation, G.D.F. and S.V.; writing—review and editing, G.D.F.; visualization, G.D.F.; supervision, M.M. (Marianna Meschiari). All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Data Availability Statement

Data available on request from corresponding author due to privacy restrictions.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Könönen, E.; Wade, W.G. Actinomyces and Related Organisms in Human Infections. Clin. Microbiol. Rev. 2015, 28, 419–442. [Google Scholar] [CrossRef] [PubMed]
  2. Wong, V.K.; Turmezei, T.D.; Weston, V.C. Actinomycosis. BMJ 2011, 343, d6099. [Google Scholar] [CrossRef] [PubMed]
  3. Acevedo, F.; Baudrand, R.; Letelier, L.M.; Gaete, P. Actinomycosis: A Great Pretender. Case Reports of Unusual Presentations and a Review of the Literature. Int. J. Infect. Dis. 2008, 12, 358–362. [Google Scholar] [CrossRef] [PubMed]
  4. Skuhala, T.; Tomasović, D.; Štimac, G.; Ljubičić, N.; Oroši, D.; Stanimirović, A.; Vukelić, D. Treatment of Penile Actinomycosis. Dermatol. Ther. 2018, 31, e12636. [Google Scholar] [CrossRef] [PubMed]
  5. Clyde, M.; McAllister, J.; Obeidallah, A.; Ahmad, I. Actinomyces odontolyticus Infection 3 Months Post-Robotic-Assisted Laparoscopic Prostatectomy. BMJ Case Rep. 2019, 12, e228184. [Google Scholar] [CrossRef] [PubMed]
  6. Dagher, R.; Riaz, T.; Tande, A.J.; Osmon, D.R.; Jagtiani, A.; Steckelberg, J.M.; Mabry, T.; Berbari, E.F. Prosthetic Joint Infection Due to Actinomyces Species: A Case Series and Review of Literature. J. Bone Jt. Infect. 2019, 4, 174–180. [Google Scholar] [CrossRef] [PubMed]
  7. Phichaphop, C.; Apiwattanakul, N.; Wanitkun, S.; Boonsathorn, S. Bacterial Endocarditis Caused by Actinomyces oris: First Reported Case and Literature Review. J. Investig. Med. High Impact Case Rep. 2020, 8, 232470962091064. [Google Scholar] [CrossRef] [PubMed]
  8. Hsiao, Y.-C.; Lee, Y.-H.; Ho, C.-M.; Tseng, C.-H.; Wang, J.-H. Clinical Characteristics of Actinomyces Viscosus Bacteremia. Medicina 2021, 57, 1064. [Google Scholar] [CrossRef] [PubMed]
  9. Lyons, O.T.A.; Baguneid, M.; Barwick, T.D.; Bell, R.E.; Foster, N.; Homer-Vanniasinkam, S.; Hopkins, S.; Hussain, A.; Katsanos, K.; Modarai, B.; et al. Diagnosis of Aortic Graft Infection: A Case Definition by the Management of Aortic Graft Infection Collaboration (MAGIC). Eur. J. Vasc. Endovasc. Surg. 2016, 52, 758–763. [Google Scholar] [CrossRef]
  10. Delarbre, X.; Auzary, C.; Bahnini, A.; Nordmann, P.; Delfraissy, J.-F. Isolement d’ Actinomyces odontolyticus au cours d’une infection de prothèse aortique avec fistule duodénoparaprothétique. Rev. Méd. Interne 2007, 28, 412–415. [Google Scholar] [CrossRef]
  11. Bush, L.M.; Zad, O.; Khan, Y.; Chaparro-Rojas, F.; Hasan, S.M.; Zeltzer, J.; Perez, M.T. Polymicrobial Abdominal Aortic Endograft Infection Secondary to Aorto-Enteric Para-Prosthetic Erosion. Infect. Dis. Clin. Pract. 2009, 17, 374–377. [Google Scholar] [CrossRef]
  12. Lane, J.S.; Barleben, A.R.; Kubaska, S.M.; Fujitani, R.M. Aortoduodenal Fistula after Endovascular Aneurysm Repair Presenting with Aneurysm Sac Abscess. J. Vasc. Surg. 2009, 50, 919–920. [Google Scholar] [CrossRef] [PubMed]
  13. Hansen, B.A.; Amundsen, S.; Reikvam, H.; Wendelbo, Ø.; Pedersen, G. Non-Curative Surgery for Aortoenteric Fistula. J. Surg. Case Rep. 2017, 2017, rjx153. [Google Scholar] [CrossRef] [PubMed]
  14. Blank, J.J.; Rothstein, A.E.; Lee, C.J.; Malinowski, M.J.; Lewis, B.D.; Ridolfi, T.J.; Otterson, M.F. Aortic Graft Infection Secondary to Iatrogenic Transcolonic Graft Malposition. Vasc. Endovasc. Surg. 2018, 52, 386–390. [Google Scholar] [CrossRef] [PubMed]
  15. Howgego, G.; Howard, D. The Challenges of Diagnosing and Managing a Ruptured Abdominal Aortic Aneurysm with Primary Aortoduodenal Fistula. J. Nuffield Dep. Surg. Sci. 2021, 2. [Google Scholar] [CrossRef]
  16. Puges, M.; Pereyre, S.; Bérard, X.; Accoceberry, I.; Le Roy, C.; Stecken, L.; Pinaquy, J.-B.; Desclaux, A.; Dupon, M.; Bébéar, C.; et al. Comparison of Genus Specific PCR and Culture with or without Sonication for Microbiological Diagnosis of Vascular Graft Infection. Eur. J. Vasc. Endovasc. Surg. 2018, 56, 562–571. [Google Scholar] [CrossRef] [PubMed]
  17. Puges, M.; Bérard, X.; Caradu, C.; Ducours, M.; Eldin, C.; Carrer, M.; Sauvage, N.; Vareil, M.-O.; Alleman, L.; M’Zali, F.; et al. Polymicrobial Infections Among Patients with Vascular Q Fever, France, 2004–2020. Emerg. Infect. Dis. 2021, 27, 1961–1963. [Google Scholar] [CrossRef]
  18. Narayanan, A.; Hanna, J.; Okamura-Kho, A.; Tesar, J.; Lim, E.; Peden, S.; Dean, A.; Taumoepeau, L.; Katib, N.; Lyons, O.; et al. Management of Secondary Aorto-enteric Fistulae: A Multi-centre Study. ANZ J. Surg. 2023, 93, 2363–2369. [Google Scholar] [CrossRef]
  19. De Virgilio, C.; Cherry, K.J.; Gloviczki, P.; Naessens, J.; Bower, T.; Hallett, J.; Pairolero, P. Infected Lower Extremity Extra-Anatomic Bypass Grafts: Management of a Serious Complication in High-Risk Patients. Ann. Vasc. Surg. 1995, 9, 459–466. [Google Scholar] [CrossRef]
  20. Heo, S.-H.; Kim, Y.-W.; Woo, S.-Y.; Park, Y.-J.; Kim, D.-K.; Chung, D.-R. Recent Results of In Situ Abdominal Aortic Reconstruction with Cryopreserved Arterial Allograft. Eur. J. Vasc. Endovasc. Surg. 2017, 53, 158–167. [Google Scholar] [CrossRef]
  21. Hosaka, A.; Kumamaru, H.; Usune, S.; Miyata, H.; Goto, H. Outcomes of Surgery for Endograft Infection in the Abdominal Aorta and Iliac Artery: A Nationwide Cohort Study. Ann. Surg. 2023, 277, e963–e970. [Google Scholar] [CrossRef] [PubMed]
  22. Saeed, W.; Adam, M.; Abdallah, T.A.; Omrani, A.S. Percutaneous Coronary Intervention-Associated Actinomyces oris. IDCases 2020, 22, e00929. [Google Scholar] [CrossRef] [PubMed]
  23. Makaryus, A.N.; Latzman, J.; Yang, R.; Rosman, D. A Rare Case of Actinomyces Israelii Presenting as Pericarditis in a 75-Year-Old Man. Cardiol. Rev. 2005, 13, 125–127. [Google Scholar] [CrossRef] [PubMed]
  24. Chakfé, N.; Diener, H.; Lejay, A.; Assadian, O.; Berard, X.; Caillon, J.; Fourneau, I.; Glaudemans, A.W.J.M.; Koncar, I.; Lindholt, J.; et al. European Society for Vascular Surgery (ESVS) 2020 Clinical Practice Guidelines on the Management of Vascular Graft and Endograft Infections. Eur. J. Vasc. Endovasc. Surg. 2020, 59, 339–384. [Google Scholar] [CrossRef] [PubMed]
  25. Leroy, O.; Meybeck, A.; Sarraz-Bournet, B.; d’Elia, P.; Legout, L. Vascular Graft Infections. Curr. Opin. Infect. Dis. 2012, 25, 154–158. [Google Scholar] [CrossRef] [PubMed]
  26. Ioannou, P.; Baliou, S.; Papakitsou, I.; Kofteridis, D.P. Infective Endocarditis by Actinomyces Species: A Systematic Review. J. Chemother. 2023, 35, 87–94. [Google Scholar] [CrossRef] [PubMed]
  27. Southwood, R.; Rice, J.; McDonald, P.; Hakendorf, P.; Rozenbilds, M. Infection in Experimental Hip Arthroplasties. J. Bone Jt. Surg. Br. Vol. 1985, 67, 229–231. [Google Scholar] [CrossRef]
  28. Lovati, A.B.; Bottagisio, M.; De Vecchi, E.; Gallazzi, E.; Drago, L. Animal Models of Implant-Related Low-Grade Infections. A Twenty-Year Review. In A Modern Approach to Biofilm-Related Orthopaedic Implant Infections; Drago, L., Ed.; Advances in Experimental Medicine and Biology; Springer International Publishing: Cham, Switzerland, 2016; Volume 971, pp. 29–50. ISBN 978-3-319-52273-9. [Google Scholar]
  29. García-García, A.; Ramírez-Durán, N.; Sandoval-Trujillo, H.; Romero-Figueroa, M.D.S. Pelvic Actinomycosis. Can. J. Infect. Dis. Med. Microbiol. 2017, 2017, 9428650. [Google Scholar] [CrossRef]
  30. Brunner, S.; Graf, S.; Riegel, P.; Altwegg, M. Catalase-Negative Actinomyces neuii Subsp. neuii Isolated from an Infected Mammary Prosthesis. Int. J. Med. Microbiol. 2000, 290, 285–287. [Google Scholar] [CrossRef]
  31. Garelick, J.M.; Khodabakhsh, A.J.; Josephberg, R.G. Acute Postoperative Endophthalmitis Caused by Actinomyces neuii. Am. J. Ophthalmol. 2002, 133, 145–147. [Google Scholar] [CrossRef]
  32. Tagowski, M.; Vieweg, H.; Wissgott, C.; Andresen, R. Aortoenteric Fistula as a Complication of Open Reconstruction and Endovascular Repair of Abdominal Aorta. Radiol. Res. Pract. 2014, 2014, 383159. [Google Scholar] [CrossRef] [PubMed]
  33. Miura, S.; Kurimoto, Y.; Ujihira, K.; Masuda, T.; Yanase, Y.; Iba, Y.; Maruyama, R.; Yamada, A. Emergency Endovascular Aneurysm Repair Coupled with Staged Omentopexy for Primary Aorto-Duodenal Fistula. Ann. Vasc. Dis. 2020, 13, 183–186. [Google Scholar] [CrossRef] [PubMed]
  34. Grewing, A.; Jujjavarapu, H.; Price, C.; Eilers, L.F.; Zimmerman, S.; Hiermandi, N.; Qureshi, A.M.; Kellermayer, R.; Britt, J.J. Esophageal Lesion Reveals an Aortic Pseudoaneurysm in the Setting of Actinomyces odontolyticus Bacteremia. JACC Case Rep. 2023, 15, 101867. [Google Scholar] [CrossRef] [PubMed]
  35. Da Silva, R.M.; Lingaas, P.S.; Geiran, O.; Tronstad, L.; Olsen, I. Multiple Bacteria in Aortic Aneurysms. J. Vasc. Surg. 2003, 38, 1384–1389. [Google Scholar] [CrossRef] [PubMed]
  36. Clarridge, J.E.; Zhang, Q. Genotypic Diversity of Clinical Actinomyces Species: Phenotype, Source, and Disease Correlation among Genospecies. J. Clin. Microbiol. 2002, 40, 3442–3448. [Google Scholar] [CrossRef] [PubMed]
  37. Alamillos-Granados, F.J.; Dean-Ferrer, A.; García-López, A.; López-Rubio, F. Actinomycotic Ulcer of the Oral Mucosa: An Unusual Presentation of Oral Actinomycosis. Br. J. Oral Maxillofac. Surg. 2000, 38, 121–123. [Google Scholar] [CrossRef] [PubMed]
  38. Pulverer, G.; Schütt-Gerowitt, H.; Schaal, K.P. Human Cervicofacial Actinomycoses: Microbiological Data for 1997 Cases. Clin. Infect. Dis. 2003, 37, 490–497. [Google Scholar] [CrossRef]
  39. Thacker, S.A.; Healy, C.M. Pediatric Cervicofacial Actinomycosis: An Unusual Cause of Head and Neck Masses. J. Pediatr. Infect. Dis. Soc. 2014, 3, e15–e19. [Google Scholar] [CrossRef]
  40. Lensing, F.; Abele, T.; Wiggins, R.; Quigley, E. Laryngeal Actinomycosis. Bayl. Univ. Med. Cent. Proc. 2014, 27, 35–36. [Google Scholar] [CrossRef]
  41. Kelti, M.; Jonathan, M.; Timothy, B. A Rare Case of Actinomyces odontolyticus Infection after Injection Laryngoplasty with Deflux. J. Otolaryngol. Rhinol. 2020, 6, 092. [Google Scholar] [CrossRef]
  42. Takiguchi, Y.; Terano, T.; Hirai, A. Lung Abscess Caused by Actinomyces odontolyticus. Intern. Med. 2003, 42, 723–725. [Google Scholar] [CrossRef] [PubMed]
  43. Pérez-Castrillón, J.L.; Gonzalez-Castaneda, C.; Del Campo-Matias, F.; Bellido-Casado, J.; Diaz, G. Empyema Necessitatis Due to Actinomyces odontolyticus. Chest 1997, 111, 1144. [Google Scholar] [CrossRef] [PubMed]
  44. Diab, C.; Almarzouq, A.; Ajise, O.; Barkati, S.; Tchervenkov, J.; Andonian, S. Renal Actinomycosis Presenting as Uro-Cutaneous Fistula. Urol. Case Rep. 2020, 28, 101054. [Google Scholar] [CrossRef] [PubMed]
  45. Fulton, H.M.; Shirley, R.M. Renal Actinomycosis with Muscular Invasion Post-Nephrostomy Tube Placement. IDCases 2022, 29, e01586. [Google Scholar] [CrossRef] [PubMed]
  46. Mitchell, R.G.; Crow, M.R. Actinomyces odontolyticus Isolated from the Female Genital Tract. J. Clin. Pathol. 1984, 37, 1379–1383. [Google Scholar] [CrossRef] [PubMed]
  47. Pană, A.G.; Neculicioiu, V.; Toc, D.A.; Sprinjan, G.D.; Rusu, M.C.; Costache, C. Tubo-Ovarian Abscess with Actinomyces odontolyticus: Case Report and Brief Review of Literature. Reports 2022, 5, 46. [Google Scholar] [CrossRef]
  48. Lopes, V.N.; Dantas, M.J.; Andrade, P.; Pinto-de-Sousa, J. Secondary Peritonitis by Actinomyces odontolyticus. Porto Biomed. J. 2017, 2, 174–175. [Google Scholar] [CrossRef]
  49. Furuya, K.; Ito, K.; Sugiyama, K.; Fujita, A.; Kanemoto, H.; Shimada, T. A Case of Recurrent Acute Cholecystitis Caused by Actinomyces odontolyticus, Rare Actinomycosis. BMC Infect. Dis. 2022, 22, 518. [Google Scholar] [CrossRef]
  50. Chao, C.-T.; Liao, C.-H.; Lai, C.-C.; Hsueh, P.-R. Liver Abscess Due to Actinomyces odontolyticus in an Immunocompetent Patient. Infection 2011, 39, 77–79. [Google Scholar] [CrossRef]
  51. Hsu, S.-L.; Wu, C.-T.; Chang, Y.-C.; Fan, C.-K.; Lee, Y.-J. Case Report of an Unusual Hepatic Abscess Caused by Actinomyces odontolyticus in a Patient with Human Immunodeficiency Virus Infection. BMC Infect. Dis. 2021, 21, 998. [Google Scholar] [CrossRef]
  52. Schaal, K.P.; Lee, H.-J. Actinomycete Infections in Humans—A Review. Gene 1992, 115, 201–211. [Google Scholar] [CrossRef] [PubMed]
  53. Patil, V.; Joshi, A.; Joshi, S.; Patel, D. Lumbosacral Actinomycosis in an Immunocompetent Individual: An Extremely Rare Case. J. Craniovert. Jun. Spine 2014, 5, 173. [Google Scholar] [CrossRef] [PubMed]
  54. Jain, H.; Singh, G.; Eranki, A. Actinomyces odontolyticus Causing Meningitis and Cervical Abscess. Bayl. Univ. Med. Cent. Proc. 2021, 34, 492–493. [Google Scholar] [CrossRef] [PubMed]
  55. Yesilbas, O.; Yozgat, C.Y.; Nizam, O.G.; Bursal Duramaz, B.; Turel, O. Life-threatening Multiple Brain Abscesses Secondary to Actinomyces odontolyticus. Pediatr. Int. 2020, 62, 1307–1308. [Google Scholar] [CrossRef]
  56. Davanos, E.; Rahman, S.M.; Nogid, B. Treatment of Eikenella Corrodens and Actinomyces odontolyticus Foot Abscess in a Penicillin-Allergic Patient. Ann. Pharmacother. 2008, 42, 1706–1710. [Google Scholar] [CrossRef] [PubMed]
  57. Prashant, N.; Azuhairy, A. Actinomycosis of Distal Phalanx Twenty Years after Flap Reconstruction of Index Finger: A Case Report. Malays. Orthop. J. 2018, 12, 48–50. [Google Scholar] [CrossRef] [PubMed]
  58. Peloux, Y.; Raoult, D.; Chardon, H.; Escarguel, J. Actinomyces odontolyticus Infections: Review of Six Patients. J. Infect. 1985, 11, 125–129. [Google Scholar] [CrossRef]
  59. Rich, B.S.; Angeles, C.; Barie, P.S. Actinomyces odontolyticus Breast Abscess. Surg. Infect. 2013, 14, 331–332. [Google Scholar] [CrossRef]
  60. Sofianou, D.; Avgoustinakis, E.; Dilopoulou, A.; Pournaras, S.; Tsirakidis, G.; Tsakris, A. Soft-Tissue Abscess Involving Actinomyces odontolyticus and Two Prevotella Species in an Intravenous Drug Abuser. Comp. Immunol. Microbiol. Infect. Dis. 2004, 27, 75–79. [Google Scholar] [CrossRef]
  61. Harvey, P.; Bayardelle, P.; Bélanger, R.; Fortin, L. Sacroiliitis and Septicemia Caused by Campylobacter Rectus and Actinomyces odontolyticus. Can. J. Infect. Dis. 1994, 5, 133–136. [Google Scholar] [CrossRef]
  62. Marques, P.M.; Quaresma, M.M.; Haghighi, E.; Barata, J.A. Radiation Proctitis-Related Lumbar Spondylodiscitis Due to Actinomyces odontolyticus: A Rare Finding. BMJ Case Rep. 2021, 14, e237047. [Google Scholar] [CrossRef] [PubMed]
  63. Mack, R.; Slicker, K.; Ghamande, S.; Surani, S.R. Actinomyces odontolyticus: Rare Etiology for Purulent Pericarditis. Case Rep. Med. 2014, 2014, 734925. [Google Scholar] [CrossRef] [PubMed]
  64. Broly, E.; Risse, J.; Maschino, F.; Wahl, D. Cardiac Tamponade Due to Actinomyces odontolyticus Originating from a Dentigerous Cyst. J. Oral Maxillofac. Surg. 2016, 74, 2453–2456. [Google Scholar] [CrossRef] [PubMed]
  65. Patel, K.; MacDonald, M.; Hmoud, H.; Czinn, E.; Wutawunashe, C.; Fisher, P. Aortic Valve Endocarditis by Actinomyces odontolyticus and Gemella morbillorum Oral Pathogens. IDCases 2021, 24, e01079. [Google Scholar] [CrossRef] [PubMed]
  66. Cone, L.A.; Leung, M.M.; Hirschberg, J. Actinomyces odontolyticus Bacteremia. Emerg. Infect. Dis. 2003, 9, 1629–1632. [Google Scholar] [CrossRef] [PubMed]
  67. Weiand, D.; Barlow, G. The Rising Tide of Bloodstream Infections with Actinomyces Species: Bimicrobial Infection with Actinomyces odontolyticus and Escherichia Coli in an Intravenous Drug User. Oxf. Med. Case Rep. 2014, 2014, 156–158. [Google Scholar] [CrossRef] [PubMed]
  68. Rueda, M.S.; Hefter, Y.; Stone, B.; Hahn, A.; Jantausch, B. A Premature Infant With Neonatal Actinomyces odontolyticus Sepsis. J. Pediatr. Infect. Dis. Soc. 2021, 10, 533–535. [Google Scholar] [CrossRef]
  69. Ali, M.; Razok, A.; Ziglam, H. A 5-Year Retrospective Study of Actinomyces odontolyticus Bacteremia in the State of Qatar, Case Series. Ann. Med. Surg. 2022, 76. [Google Scholar] [CrossRef]
  70. Farah Khoury, M.; Perek, S.; Raz-Pasteur, A. Implantable Cardioverter Defibrillator Related Actinomyces odontolyticus Endocarditis and Bacteremia—First Reported Case. IDCases 2021, 25, e01228. [Google Scholar] [CrossRef]
  71. Hall, V.; Talbot, P.R.; Stubbs, S.L.; Duerden, B.I. Identification of Clinical Isolates of Actinomyces Species by Amplified 16S Ribosomal DNA Restriction Analysis. J. Clin. Microbiol. 2001, 39, 3555–3562. [Google Scholar] [CrossRef]
  72. Woo, P.C.Y.; Fung, A.M.Y.; Lau, S.K.P.; Hon, E.; Yuen, K. Diagnosis of Pelvic Actinomycosis by 16S Ribosomal RNA Gene Sequencing and Its Clinical Significance. Diagn. Microbiol. Infect. Dis. 2002, 43, 113–118. [Google Scholar] [CrossRef]
  73. Sarkonen, N.; Könönen, E.; Eerola, E.; Könönen, M.; Jousimies-Somer, H.; Laine, P. Characterization of Actinomyces Species Isolated from Failed Dental Implant Fixtures. Anaerobe 2005, 11, 231–237. [Google Scholar] [CrossRef] [PubMed]
  74. Khiatah, B.; Shah, K.; Belikova, A.; Saeed, M. Sepsis Due to Actinomyces odontolyticus as a Rare Complication of Neobladder. Case Rep. Infect. Dis. 2021, 2021, 6699046. [Google Scholar] [CrossRef] [PubMed]
  75. Lafaurie, G.I.; Mayorga-Fayad, I.; Torres, M.F.; Castillo, D.M.; Aya, M.R.; Barón, A.; Hurtado, P.A. Periodontopathic Microorganisms in Peripheric Blood after Scaling and Root Planing. J. Clin. Periodontol. 2007, 34, 873–879. [Google Scholar] [CrossRef] [PubMed]
  76. Vaziri, N.D.; Yuan, J.; Nazertehrani, S.; Ni, Z.; Liu, S. Chronic Kidney Disease Causes Disruption of Gastric and Small Intestinal Epithelial Tight Junction. Am. J. Nephrol. 2013, 38, 99–103. [Google Scholar] [CrossRef] [PubMed]
  77. Syed-Ahmed, M.; Narayanan, M. Immune Dysfunction and Risk of Infection in Chronic Kidney Disease. Adv. Chronic Kidney Dis. 2019, 26, 8–15. [Google Scholar] [CrossRef] [PubMed]
  78. Yamada, Y.; Kinoshita, C.; Nakagawa, H. Lumbar Vertebral Osteomyelitis and Psoas Abscess Caused by Actinomyces Israelii after an Operation under General Anesthesia in a Patient with End-Stage Renal Disease: A Case Report. J. Med. Case Rep. 2019, 13, 351. [Google Scholar] [CrossRef]
  79. Hsueh, L.; Kacharam, S.; Shah, A.D. A Rare Case of Actinomyces Skin and Soft Tissue Infection in an End-stage Kidney Disease Patient with a Review of the Literature. Hemodial. Int. 2020, 24, E40–E45. [Google Scholar] [CrossRef]
  80. Ferry, T.; Valour, F.; Karsenty, J.; Breton, P.; Gleizal, A.; Braun, E.; Chidiac, C.; Ader, F.; Senechal, A.; Dupieux, C.; et al. Actinomycosis: Etiology, Clinical Features, Diagnosis, Treatment, and Management. Infect. Drug Resist. 2014, 7, 183–197. [Google Scholar] [CrossRef]
  81. Fong, P.; Francis, M.J.; Hamblin, J.F.; Korman, T.M.; Graham, M. Identification and Diversity of Actinomyces Species in a Clinical Microbiology Laboratory in the MALDI-TOF MS Era. Anaerobe 2018, 54, 151–158. [Google Scholar] [CrossRef]
  82. Bonnefond, S.; Catroux, M.; Melenotte, C.; Karkowski, L.; Rolland, L.; Trouillier, S.; Raffray, L. Clinical Features of Actinomycosis: A Retrospective, Multicenter Study of 28 Cases of Miscellaneous Presentations. Medicine 2016, 95, e3923. [Google Scholar] [CrossRef] [PubMed]
  83. Lewis, R.; McKenzie, D.; Bagg, J.; Dickie, A. Experience with a Novel Selective Medium for Isolation of Actinomyces Spp. from Medical and Dental Specimens. J. Clin. Microbiol. 1995, 33, 1613–1616. [Google Scholar] [CrossRef] [PubMed]
  84. Carrara, J.; Hervy, B.; Dabi, Y.; Illac, C.; Haddad, B.; Skalli, D.; Miailhe, G.; Vidal, F.; Touboul, C.; Vaysse, C. Added-Value of Endometrial Biopsy in the Diagnostic and Therapeutic Strategy for Pelvic Actinomycosis. J. Clin. Med. 2020, 9, 821. [Google Scholar] [CrossRef] [PubMed]
  85. Panya, S.; Fliefel, R.; Probst, F.; Tröltzsch, M.; Ehrenfeld, M.; Schubert, S.; Otto, S. Role of Microbiological Culture and Polymerase Chain Reaction (PCR) of Actinomyces in Medication-Related Osteonecrosis of the Jaw (MRONJ). J. Cranio-Maxillofac. Surg. 2017, 45, 357–363. [Google Scholar] [CrossRef]
  86. Kaya, D.; Demirezen, Ş.; Hasçelik, G.; Gülmez Kıvanç, D.; Beksaç, M.S. Comparison of PCR, Culturing and Pap Smear Microscopy for Accurate Diagnosis of Genital Actinomyces. J. Med. Microbiol. 2013, 62, 727–733. [Google Scholar] [CrossRef] [PubMed]
  87. Kokosar Ulcar, B.; Lakic, N.; Jeverica, S.; Pecavar, B.; Logar, M.; Cerar, T.K.; Lejko-Zupanc, T. Contribution of Sonicate-Fluid Cultures and Broad-Range PCR to Microbiological Diagnosis in Vascular Graft Infections. Infect. Dis. 2018, 50, 429–435. [Google Scholar] [CrossRef] [PubMed]
  88. Partovi, S.; Trischman, T.; Sheth, R.A.; Huynh, T.T.T.; Davidson, J.C.; Prabhakar, A.M.; Ganguli, S. Imaging Work-up and Endovascular Treatment Options for Aorto-Enteric Fistula. Cardiovasc. Diagn. Ther. 2018, 8, S200–S207. [Google Scholar] [CrossRef]
  89. Niaz, O.S.; Rao, A.; Abidia, A.; Parrott, R.; Refson, J.; Somaiya, P. Surgical and Medical Interventions for Abdominal Aortic Graft Infections. Cochrane Database Syst. Rev. 2020. [Google Scholar] [CrossRef]
  90. Wilson, W.R.; Bower, T.C.; Creager, M.A.; Amin-Hanjani, S.; O’Gara, P.T.; Lockhart, P.B.; Darouiche, R.O.; Ramlawi, B.; Derdeyn, C.P.; Bolger, A.F.; et al. Vascular Graft Infections, Mycotic Aneurysms, and Endovascular Infections: A Scientific Statement From the American Heart Association. Circulation 2016, 134, e412–e460. [Google Scholar] [CrossRef]
  91. Choi, J.; Koh, W.-J.; Kim, T.S.; Lee, K.S.; Han, J.; Kim, H.; Kwon, O.J. Optimal Duration of IV and Oral Antibiotics in the Treatment of Thoracic Actinomycosis. Chest 2005, 128, 2211–2217. [Google Scholar] [CrossRef]
  92. Moghimi, M.; Salentijn, E.; Debets-Ossenkop, Y.; Karagozoglu, K.; Forouzanfar, T. Treatment of Cervicofacial Actinomycosis: A Report of 19 Cases and Review of Literature. Med. Oral 2013, 18, e627–e632. [Google Scholar] [CrossRef] [PubMed]
  93. Sudhakar, S.S.; Ross, J.J. Short-Term Treatment of Actinomycosis: Two Cases and a Review. Clin. Infect. Dis. 2004, 38, 444–447. [Google Scholar] [CrossRef] [PubMed]
  94. Smith, A.J.; Hall, V.; Thakker, B.; Gemmell, C.G. Antimicrobial Susceptibility Testing of Actinomyces Species with 12 Antimicrobial Agents. J. Antimicrob. Chemother. 2005, 56, 407–409. [Google Scholar] [CrossRef] [PubMed]
  95. LeCorn, D.W.; Vertucci, F.J.; Rojas, M.F.; Progulske-Fox, A.; Bélanger, M. In Vitro Activity of Amoxicillin, Clindamycin, Doxycycline, Metronidazole, and Moxifloxacin Against Oral Actinomyces. J. Endod. 2007, 33, 557–560. [Google Scholar] [CrossRef]
  96. Marchand-Austin, A.; Rawte, P.; Toye, B.; Jamieson, F.B.; Farrell, D.J.; Patel, S.N. Antimicrobial Susceptibility of Clinical Isolates of Anaerobic Bacteria in Ontario, 2010–2011. Anaerobe 2014, 28, 120–125. [Google Scholar] [CrossRef] [PubMed]
  97. Steininger, C.; Willinger, B. Resistance Patterns in Clinical Isolates of Pathogenic Actinomyces Species. J. Antimicrob. Chemother. 2016, 71, 422–427. [Google Scholar] [CrossRef] [PubMed]
  98. Barberis, C.; Budia, M.; Palombarani, S.; Rodriguez, C.H.; Ramírez, M.S.; Arias, B.; Bonofiglio, L.; Famiglietti, A.; Mollerach, M.; Almuzara, M.; et al. Antimicrobial Susceptibility of Clinical Isolates of Actinomyces and Related Genera Reveals an Unusual Clindamycin Resistance among Actinomyces Urogenitalis Strains. J. Glob. Antimicrob. Resist. 2017, 8, 115–120. [Google Scholar] [CrossRef] [PubMed]
  99. Kolditz, M.; Bickhardt, J.; Matthiessen, W.; Holotiuk, O.; Hoffken, G.; Koschel, D. Medical Management of Pulmonary Actinomycosis: Data from 49 Consecutive Cases. J. Antimicrob. Chemother. 2009, 63, 839–841. [Google Scholar] [CrossRef]
  100. Kaur, M.; Bains, A.; Bhardwaj, A.; Patra, S.; Kumar, D.; Aggarwal, D.; Yadav, T. An Intriguing Case of Scalp Actinomycosis with Brain and Eye Involvement: Successful Treatment with Ceftriaxone. Clin. Exp. Dermatol. 2023, 48, 1050–1052. [Google Scholar] [CrossRef]
  101. De Leoz, J.B.; Suravajjala, D.; Rafeek, H.; Selvan, V. Primary Mammary Actinomycosis Challenged with Penicillin Allergy. BMJ Case Rep. 2021, 14, e235883. [Google Scholar] [CrossRef]
  102. Maraki, S.; Mavromanolaki, V.E.; Stafylaki, D.; Kasimati, A. Antimicrobial Susceptibility Patterns of Clinically Significant Gram-Positive Anaerobic Bacteria in a Greek Tertiary-Care Hospital, 2017–2019. Anaerobe 2020, 64, 102245. [Google Scholar] [CrossRef] [PubMed]
  103. Wolff, A.; Rodloff, A.C.; Vielkind, P.; Borgmann, T.; Stingu, C.-S. Antimicrobial Susceptibility of Clinical Oral Isolates of Actinomyces Spp. Microorganisms 2022, 10, 125. [Google Scholar] [CrossRef] [PubMed]
  104. Cooley, L.; Teng, J. Anaerobic Resistance: Should We Be Worried? Curr. Opin. Infect. Dis. 2019, 32, 523–530. [Google Scholar] [CrossRef] [PubMed]
Table 1. Demographic and clinical characteristics of Actinomyces-PVGI cases occurred in the last five years in the University Hospitals of Brescia and Modena.
Table 1. Demographic and clinical characteristics of Actinomyces-PVGI cases occurred in the last five years in the University Hospitals of Brescia and Modena.
NAge (y),
Sex (M/F)
ComorbiditiesAortic Prosthesis ImplantClinical Picture
Reason for Primary Vascular Implant (Type of Procedure)Time from Implant to PresentationPresentationAorto-Enteric Fistula
173, MAppendectomy, previous AKI on CVVHAAA rupture with intestinal ischemia (EVAR and sigmoidectomy)7 mAbdominal pain and hemoptysisYes
(ileum)
281, MHypertension, atrial fibrillation, previous SARS-CoV-2 pneumoniainfectious AAA due to Salmonella spp. (EVAR)6 mFever and lumbar painNot identified
377, MDialysisAAA (aorto-biiliac prosthesis, procedure unknown)4 yFever, lumbar pain and intestinal bleedingYes (duodenum)
469, MCardias adenocarcinoma treated surgically + chemotherapy + radiotherapy, complicated with esophageal fistula surgically repaired (10 y before), previous lymphomainfectious AAA rupture secondary to gastrointestinal infection (EVAR and PTA of left common iliac artery)4 mLow-grade fever and septic shockNot identified
576, FMammary carcinoma treated surgically (4 y), left TKA, intestinal subocclusion (2 y), COPD, hypertensive cardiomyopathy,
amoxicillin allergy (rash)
infectious AAA rupture due to Salmonella spp. (EVAR) with subsequent abscessualization of aneurysmatic sac and vertebral osteomyelitis requiring surgical drainage and spine stabilization10 mS. aureus vertebral implant infection with wound dehiscence later complicated with polymicrobial BSIsNot identified
Abbreviations: N: number; M: male; F: female; AKI: acute kidney injury; CVVH: continuous veno–venous hemofiltration; COPD: chronic obstructive pulmonary disease; PTA: percutaneous transluminal angioplasty; TKA: total knee arthroplasty; AAA: abdominal aortic aneurysm; EVAR: endovascular repair; d: days; w: weeks; m: months; y: years.
Table 2. Microbiological characteristics, treatment, and outcomes of Actinomyces-PVGI cases that occurred in the last five years at the University Hospitals of Brescia and Modena.
Table 2. Microbiological characteristics, treatment, and outcomes of Actinomyces-PVGI cases that occurred in the last five years at the University Hospitals of Brescia and Modena.
NMicrobiological ResultsTreatmentOutcome
Antibiotic TherapySurgery
1A. odontolyticus (I)
C. albicans (I)
iv: meropenem + micafungin (2 w)
then os:
amoxicillin (long-term) + fluconazole (11 m)
Explant and substitutionPeriprosthetic abscess of the psoas muscle (2 y f-up)
2A. odontolyticus (I)
Salmonella spp. (I)
iv: ceftriaxone + ampicillin (12 w)
then os: amoxicillin (10 m)
Explant and substitutionRecovered (2 y f-up)
3A. odontolyticus (B)os: amoxicillin (long-term)Not performedDeath (37 d)
4A. odontolyticus (B)
S. anginosus (B)
Salmonella spp. (S)
iv: daptomycin + amoxi/clav. (3 w)
then os: amoxiclav. (15 d)
Explant and bypassRecovered (3 y f-up)
5Actinomyces spp. (B)
S. aureus (B)
E. coli (B)
iv: meropenem (2 w)
then os: cotrimoxazole + rifampin (long-term)
Not performedDeath (7 m)
Abbreviations: d: days; m: months; y: years; B: blood cultures; I: intraoperative; S: stool cultures; iv: intravenous therapy; os: oral therapy.
Table 3. Demographic and clinical characteristics of Actinomyces-PVGI cases retrieved from the literature review.
Table 3. Demographic and clinical characteristics of Actinomyces-PVGI cases retrieved from the literature review.
Case ReportAge (y),
Sex (M/F)
ComorbiditiesAortic Prosthesis ImplantClinical Picture
Reason for Primary Vascular Implant (Type of Procedure)Time from Implant to PresentationPresentationAorto-Enteric Fistula (AEF)
Delarbre (2007) [10]73, MPeripheral obliterant arteriopathy, arterial hypertension, dyslipidemia, COPD, CKD, periodontal diseasePeripheral obliterant arteriopathy (aortobiiliac prosthesis, OSR)7 yFever and lumbar painYes (duodenum)
Bush (2009) [11]79, M-- (EVAR)8 yFever and abdominal pain irradiating to the backYes (duodenum)
Lane (2009) [12] 69, M-Infrarenal AAA (EVAR)6 mFever, lethargy, diarrheaYes (duodenum)
Hansen (2017) [13]75, M-Ruptured infrarenal AAA (EVAR) complicated with graft infection (isolation of S. milleri, E. corrodens, Bacteroides sp.) at 2 y, treated with graft revision (without explant), AEF closure, antibiotic therapy (meropenem iv followed by ciprofloxacin and clindamycin for 3 m)4 yFeverYes (duodenum)
Blank (2017) [14]54, MHypertension, hyperlipidemia, asthma, diverticulitisAcute limb ischemia (open aortobifemoral bypass)6 mFever, left leg painYes *
(sigmoid colon)
Puges (2018) [16]--->4 m-Yes (-)
Howgego (2021) [15]68, M-Ruptured AAA with primary AEF (EVAR) complicated with graft infection at 3 m, treated with graft revision (without explant) and long-term amoxiclavulanate 1 ySepsisNo
Puges (2021) [17]78, M--6 yFever, back pain and acute respiratory failureNo ^
Abbreviations: CKD: chronic kidney disease; COPD: chronic obstructive pulmonary disease; EVAR: endovascular repair; d: days; m: months; y: years; OSR: open surgical repair. * Unclear if the AEF was secondary to a technical error during graft placement. ^ Close aortoduodenal contact.
Table 4. Microbiological characteristics, treatment, and outcomes of Actinomyces-PVGI cases retrieved from the literature review.
Table 4. Microbiological characteristics, treatment, and outcomes of Actinomyces-PVGI cases retrieved from the literature review.
Case ReportMicrobiological ResultsTreatmentOutcome
Antibiotic TherapySurgery
Delarbre (2007) [10]A. odontolyticus (B)
E. coli (B, I)
E. faecium (I)
Candida albicans (I)
First (conservative)
iv: amoxicillin iv (3 w) + gentamicin (10 d);
then os: amoxicillin (8 m)
First:
Not performed
First:
failure;
Second:
iv: imipenem + amikacin + fluconazole (2 w)
Second:
Explant and graft replacement
Second:
Recovered (6 y f-up)
Bush (2009) [11]Actinomyces spp. (B)
S. constellatus (B, I)
P. melaninogenica (B)
S. lugdunensis (I)
iv: ampic./sulbactam (8 w)Explant and axillo-bifemoral graft bypassRecovered (2 m f-up)
Lane (2009) [12]A. israelii (I)
B. fragilis (I)
Unknown (“suppressive antibiotics”)Explant and
axillo-bifemoral graft bypass
Discharged (-)
Hansen (2017) [13]Actinomyces spp. (B)Unknown (“suppressive antibiotics”)Not performedRecurrent sepsis and digestive bleeding (alive at 12 y f.up)
Blank (2017) [14]A. odontolyticus (I)
S. epidermidis (I)
S. anginosus (I)
iv: tigecycline (6 w)
then os: doxycicline (6 w)
Explant and axillary-femoral bypass, colectomy Recovered (1 y f-up)
Puges (2018) [16]A. odontolyticus (I)
K. pneumoniae (I)
V. parvula (I)
C. albicans (I)
C. tropicalis (I)
---
Howgego (2021) [15]Actinomyces spp. (B)
E. faecium (B)
iv: meropenem (later ertapenem) + vancomycin (later teicoplanin)
then: long-term amoxiclavulanate
Not performedDischarged, permanent kidney dysfunction (-)
Puges (2021) [17]A. odontolyticus (I)
S. anginosus (I)
S. oralis (I, B)
Coxiella burnetii (serology and PCR)
Unknown
(no Coxiella treatment)
-Died at 37 d
Abbreviations: d: days; m: months; y: years; B: blood cultures; I: intraoperative; iv: intravenous therapy; os: oral therapy.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Del Fabro, G.; Volpi, S.; Fumarola, B.; Migliorati, M.; Bertelli, D.; Signorini, L.; Matteelli, A.; Meschiari, M. Actinomyces spp. Prosthetic Vascular Graft Infection (PVGI): A Multicenter Case-Series and Narrative Review of the Literature. Microorganisms 2023, 11, 2931. https://doi.org/10.3390/microorganisms11122931

AMA Style

Del Fabro G, Volpi S, Fumarola B, Migliorati M, Bertelli D, Signorini L, Matteelli A, Meschiari M. Actinomyces spp. Prosthetic Vascular Graft Infection (PVGI): A Multicenter Case-Series and Narrative Review of the Literature. Microorganisms. 2023; 11(12):2931. https://doi.org/10.3390/microorganisms11122931

Chicago/Turabian Style

Del Fabro, Giovanni, Sara Volpi, Benedetta Fumarola, Manuela Migliorati, Davide Bertelli, Liana Signorini, Alberto Matteelli, and Marianna Meschiari. 2023. "Actinomyces spp. Prosthetic Vascular Graft Infection (PVGI): A Multicenter Case-Series and Narrative Review of the Literature" Microorganisms 11, no. 12: 2931. https://doi.org/10.3390/microorganisms11122931

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop